CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Crystalys gets $130M to take Sobi-rivaling gout drug to market

Positive
AI Analysis

Summary

Crystalys Therapeutics raised $130 million in Series B funding to commercialize a gout drug that is already approved in Japan and China for the US and European markets.

Importance:6/10
Sentiment:
0.70
Series B FundingGoutGeographic ExpansionRegulatory Approval
Related Companies

Read the original article

Published by Endpoints News on July 22, 2026 12:00 PM

Read Original